Helixgate

Helixgate

Uncategorized

STAT+: Cigna will exit ACA individual markets next year, adding to tumult for patients

Cigna is pulling out of the Affordable Care Act’s individual marketplaces in 2027 to focus on more promising parts of its business, another exit from what’s become a tumultuous piece of the insurance industry. 

Executives announced the decision on Cigna’s first quarter earnings call on Thursday, in which the company unveiled better-than-expected financial results, including $1.7 billion in profit, and a bumped-up earnings forecast for the year. Cigna currently has 369,000 ACA members across 11 states, a small portion of its 18.3 million total members.

Brian Evanko, Cigna’s chief operating officer, said on the call that Cigna did not take the decision lightly. He said it was driven by two main factors: Cigna did not see a way to meaningfully grow that business and cutting it would free Cigna to focus on priorities like its Evernorth specialty and care services division, its pharmacy benefits division, and its flagship employer plan business. 

Continue to STAT+ to read the full story…

Read More

Published

on

Cigna is pulling out of the Affordable Care Act’s individual marketplaces in 2027 to focus on more promising parts of its business, another exit from what’s become a tumultuous piece of the insurance industry. 

Executives announced the decision on Cigna’s first quarter earnings call on Thursday, in which the company unveiled better-than-expected financial results, including $1.7 billion in profit, and a bumped-up earnings forecast for the year. Cigna currently has 369,000 ACA members across 11 states, a small portion of its 18.3 million total members.

Brian Evanko, Cigna’s chief operating officer, said on the call that Cigna did not take the decision lightly. He said it was driven by two main factors: Cigna did not see a way to meaningfully grow that business and cutting it would free Cigna to focus on priorities like its Evernorth specialty and care services division, its pharmacy benefits division, and its flagship employer plan business. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Where ‘democracy met science,’ 50 years ago

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. At a Cambridge bar on Saturday, I watched straight-seeming couples congregate by a television showing basketball, while a more queer-coded crowd lingered at another showing soccer. I don’t think that’s anything, really, but it was fun. 

This ‘never event’ is happening more frequently

A child born with congenital syphilis could suffer dire consequences: bone deformities, brain damage, blindness, deafness, and more. But that should be a ‘never event’ as public health officials say: A pregnant person can receive an injectable form of penicillin to prevent the infection. Somehow, rates keep going up anyway. Between 2012 and 2024, the U.S. saw an 800% increase in babies born with the disease. And since last year, there’s been a shortage of the drug.

Continue to STAT+ to read the full story…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. At a Cambridge bar on Saturday, I watched straight-seeming couples congregate by a television showing basketball, while a more queer-coded crowd lingered at another showing soccer. I don’t think that’s anything, really, but it was fun. 

This ‘never event’ is happening more frequently

A child born with congenital syphilis could suffer dire consequences: bone deformities, brain damage, blindness, deafness, and more. But that should be a ‘never event’ as public health officials say: A pregnant person can receive an injectable form of penicillin to prevent the infection. Somehow, rates keep going up anyway. Between 2012 and 2024, the U.S. saw an 800% increase in babies born with the disease. And since last year, there’s been a shortage of the drug.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Sanofi wins type 1 diabetes nod for Tzield after requesting to revoke CNPV

Published

on

Sanofi makes no mention of the Commissioner’s National Priority Voucher. Tzield was awarded the ticket in October 2025, but Sanofi requested withdrawal from the program after former CDER head Tracy Beth Høeg reportedly expressed skepticism of the drug.

Continue Reading

Uncategorized

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Published

on

Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.​ ​Read More

Continue Reading
Advertisement

Trending